Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYMNASDAQ:MDWDNASDAQ:PRTGNASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$1.21+0.8%$1.51$2.35▼$11.55$36M-0.39486,688 shs118,093 shsMDWDMediWound$15.04-6.0%$17.79$12.78▼$24.00$162.70M0.8289,597 shs30,798 shsPRTGPortage Biotech$5.89-2.3%$4.80$2.10▼$23.01$6.18M1.29772,179 shs24,933 shsSCPHscPharmaceuticals$2.23-3.3%$3.17$2.20▼$5.65$111.88M0.38339,826 shs208,276 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics-5.47%-8.33%-16.55%-41.55%-57.69%MDWDMediWound-1.05%-5.77%-1.96%-11.06%+6.95%PRTGPortage Biotech-13.61%+28.03%+43.57%+21.08%-41.81%SCPHscPharmaceuticals-8.00%-24.34%-30.09%-35.93%-55.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMDWDMediWound1.4402 of 5 stars3.51.00.00.00.00.80.6PRTGPortage Biotech0.5393 of 5 stars0.04.00.00.01.11.70.0SCPHscPharmaceuticals3.3924 of 5 stars3.52.00.04.20.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AMDWDMediWound 3.00Buy$31.33108.40% UpsidePRTGPortage Biotech 0.00N/AN/AN/ASCPHscPharmaceuticals 3.00Buy$14.00529.21% UpsideCurrent Analyst Ratings BreakdownLatest PRTG, SCPH, ELYM, and MDWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/3/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.002/28/2025MDWDMediWoundCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$39.001/10/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AMDWDMediWound$20.22M8.02N/AN/A$3.43 per share4.38PRTGPortage BiotechN/AN/A$10.16 per share0.58$3.74 per shareN/ASCPHscPharmaceuticals$36.33M3.08N/AN/A$1.04 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AMDWDMediWound-$6.72M-$3.07N/AN/AN/A-142.29%-82.17%-33.67%5/27/2025 (Estimated)PRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/A-342.34%-196.47%4/4/2025 (Estimated)SCPHscPharmaceuticals-$54.81M-$1.90N/AN/AN/A-264.60%-244.93%-68.56%5/13/2025 (Estimated)Latest PRTG, SCPH, ELYM, and MDWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4MDWDMediWound-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 million3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41MDWDMediWoundN/A2.111.99PRTGPortage BiotechN/A3.083.08SCPHscPharmaceuticals1.668.086.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%MDWDMediWound46.83%PRTGPortage Biotech13.36%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%MDWDMediWound9.20%PRTGPortage Biotech42.07%SCPHscPharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableMDWDMediWound8010.79 million9.79 millionOptionablePRTGPortage Biotech61.05 million608,000OptionableSCPHscPharmaceuticals3050.28 million47.28 millionOptionablePRTG, SCPH, ELYM, and MDWD HeadlinesRecent News About These CompaniesWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 11.41%April 2 at 11:54 AM | aaii.comCraig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)March 22, 2025 | markets.businessinsider.comscPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results with Major FDA Approval for FUROSCIXMarch 22, 2025 | nasdaq.comscPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim GroupMarch 21, 2025 | marketbeat.comscPharmaceuticals Full Year 2024 Earnings: In Line With ExpectationsMarch 21, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for scPharmaceuticals (NASDAQ:SCPH)March 21, 2025 | marketbeat.comscPharmaceuticals price target lowered to $12 from $20 at MaximMarch 21, 2025 | markets.businessinsider.comscPharmaceuticals (NASDAQ:SCPH) Issues Earnings ResultsMarch 20, 2025 | marketbeat.comscPharmaceuticals (NASDAQ:SCPH) Announces Quarterly Earnings ResultsMarch 20, 2025 | marketbeat.comQ4 2024 scPharmaceuticals Inc Earnings CallMarch 20, 2025 | finance.yahoo.comscPharmaceuticals reports Q 4EPS (35c), consensus (39c)March 20, 2025 | markets.businessinsider.comscPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025March 19, 2025 | msn.comScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 19, 2025 | zacks.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 19, 2025 | gurufocus.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | globenewswire.comscPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025March 12, 2025 | globenewswire.comKing Luther Capital Management Corp Buys 632,120 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)March 12, 2025 | marketbeat.comThe week in pharma: action, reaction and insight – week to March 7March 9, 2025 | thepharmaletter.comWearable Furosemide Delivery System Approved for CKD PatientsMarch 7, 2025 | empr.comFDA nod for scPharmaceuticals’ Furoscix sNDAMarch 7, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTG, SCPH, ELYM, and MDWD Company DescriptionsEliem Therapeutics NASDAQ:ELYM$1.21 +0.01 (+0.83%) As of 04/2/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.MediWound NASDAQ:MDWD$15.04 -0.97 (-6.03%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Portage Biotech NASDAQ:PRTG$5.89 -0.14 (-2.32%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.scPharmaceuticals NASDAQ:SCPH$2.22 -0.08 (-3.26%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
